Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin after radiotherapy for pediatric and young adult glioblastoma
2020-005131-74Phase 2Active
- Sponsor
- Meyer Organics
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and temozolomide in glioblastoma (GBM), sponsored by Meyer Organics. Primary endpoint: Safety and tolerability. Started May 2021; status: active.
02
Drugs
doxorubicintemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2020-005131-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005131-74.